Table 5 Changes of QLQ-BN20 over time by performance status
From: Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
| Â | KSP | Â | ||
|---|---|---|---|---|
| Â | Worsening | Stable | Improved | P value (ANCOVA) |
N = 59 | N = 49 | N = 79 | ||
| Â | Mean (SD) | Mean (SD) | Mean (SD) | Â |
Headaches * | 12.4 (29.2) | 1.2 (35.4) | -10.0 (32.6) | 0.04 |
Motor dysfunction* | 6.1 (18.8) | 0.1 (18.2) | -4.3 (15.4) | 0.01 |
Drowsiness | 5.5 (23.2) | 2.4 (27.3) | 1.7 (24.3) | 0.38 |
Weakness of legs*†| 15.2 (28.4) | -1.3 (20.2) | -12.1 (19.3) | <0.01 |
Visual disorder | 5.4 (16.1) | 2.7 (25.4) | 1.6 (22.3) | 0.64 |
Bladder control*†| 9.6 (18.8) | -0.7 (28.9) | -6.6 (26.3) | 0.01 |
Seizures | 5.3 (19.8) | 3.2 (21.8) | 2.7 (17.6) | 0.72 |
Hair loss | 12.4 (29.2) | -4.5 (50.4) | -15.2 (45.4) | 0.08 |
Itchy skin* | 6.5 (20.8) | 0.4 (26.4) | -3.8 (24.8) | 0.02 |